Press releases
- Adicet Bio Receives FDA Fast Track Designation for ADI-001 in Lupus Nephritis
- Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
- Adicet Bio to Participate in a Fireside Chat at the 2024 Jefferies Healthcare Conference
- Adicet Reports First Quarter 2024 Financial Results and Provides Business Updates
- Adicet Bio Announces Poster Presentation of ADI-270 Preclinical Data at the 2024 European Hematology Association (EHA) Hybrid Congress
- Adicet Bio to Participate in a Fireside Chat at the Citizens JMP Life Sciences Conference
- Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
- Adicet Bio Highlights Preclinical Data Supporting IND Readiness for ADI-270 in an Oral Presentation at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting
- Adicet Bio to Participate in 2024 Canaccord Genuity Horizons in Oncology Virtual Conference
- Adicet Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Company Progress
More ▼
Key statistics
On Friday, Adicet Bio Inc (1IJA:FRA) closed at 1.22, 33.46% above the 52 week low of 0.9156 set on Nov 27, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 1.22 |
---|---|
High | 1.22 |
Low | 1.22 |
Bid | 1.21 |
Offer | 1.30 |
Previous close | 1.27 |
Average volume | 0.00 |
---|---|
Shares outstanding | 82.17m |
Free float | 80.90m |
P/E (TTM) | -- |
Market cap | 111.76m USD |
EPS (TTM) | -2.95 USD |
Data delayed at least 15 minutes, as of Jun 07 2024 08:06 BST.
More ▼